James R. Mason

2.0k total citations
46 papers, 1.0k citations indexed

About

James R. Mason is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, James R. Mason has authored 46 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Hematology, 12 papers in Oncology and 10 papers in Genetics. Recurrent topics in James R. Mason's work include Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (10 papers) and Immunotherapy and Immune Responses (9 papers). James R. Mason is often cited by papers focused on Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (10 papers) and Immunotherapy and Immune Responses (9 papers). James R. Mason collaborates with scholars based in United States, Australia and India. James R. Mason's co-authors include Mansoor N. Saleh, Henry S. Loeb, Robert T. Palac, Asad Bashey, Ervin Kaplan, Sue Corringham, Robert J. Soiffer, Israel Lowy, Mildred Pasek and Ewa Carrier and has published in prestigious journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

James R. Mason

42 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James R. Mason United States 13 388 349 286 285 158 46 1.0k
Ginette Schiby Israel 18 224 0.6× 214 0.6× 219 0.8× 249 0.9× 28 0.2× 53 883
J Bernard France 18 686 1.8× 238 0.7× 188 0.7× 252 0.9× 52 0.3× 138 1.3k
Stephanie Schneider Germany 19 686 1.8× 378 1.1× 169 0.6× 408 1.4× 58 0.4× 53 1.4k
Jacqueline Vuong United States 8 485 1.3× 104 0.3× 324 1.1× 413 1.4× 27 0.2× 12 1.2k
Kaoru Takase Japan 17 184 0.5× 82 0.2× 143 0.5× 177 0.6× 51 0.3× 44 1.1k
Maya N. Polackal United States 6 580 1.5× 47 0.1× 332 1.2× 412 1.4× 79 0.5× 7 1.2k
Souichi Suenobu Japan 15 291 0.8× 124 0.4× 122 0.4× 410 1.4× 21 0.1× 56 945
J Pazdur Poland 9 297 0.8× 143 0.4× 215 0.8× 175 0.6× 84 0.5× 22 915
Satkiran S. Grewal United States 12 342 0.9× 243 0.7× 216 0.8× 368 1.3× 13 0.1× 16 1.2k
Harumi Y. Mukai Japan 19 486 1.3× 244 0.7× 190 0.7× 246 0.9× 10 0.1× 54 1.1k

Countries citing papers authored by James R. Mason

Since Specialization
Citations

This map shows the geographic impact of James R. Mason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James R. Mason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James R. Mason more than expected).

Fields of papers citing papers by James R. Mason

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James R. Mason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James R. Mason. The network helps show where James R. Mason may publish in the future.

Co-authorship network of co-authors of James R. Mason

This figure shows the co-authorship network connecting the top 25 collaborators of James R. Mason. A scholar is included among the top collaborators of James R. Mason based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James R. Mason. James R. Mason is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Murakami, Mark A., Laura Connelly‐Smith, Thomas R. Spitzer, et al.. (2024). Bone Marrow Harvest: A White Paper of Best Practices by the NMDP Marrow Alliance. Transplantation and Cellular Therapy. 30(7). 663–680. 3 indexed citations
2.
3.
Deshpande, Anagha, Darren Finlay, James R. Mason, et al.. (2022). Detection of TP53 Mutation in Acute Myeloid Leukemia by RT-PCR-Based Sanger Sequencing. Methods in molecular biology. 2594. 87–95.
4.
Bagsic, Samantha R. Spierling, et al.. (2021). ABO Phenotype and Clinical Correlates of COVID-19 Severity in Hospitalized Patients. Future Science OA. 7(8). FSO735–FSO735. 7 indexed citations
5.
Ibarra, Arkaitz, Jiali Zhuang, Yue Zhao, et al.. (2020). Non-invasive characterization of human bone marrow stimulation and reconstitution by cell-free messenger RNA sequencing. Nature Communications. 11(1). 400–400. 43 indexed citations
6.
Finlay, Darren, Rabi Murad, Karl Hong, et al.. (2020). Optical Mapping Uncovers Multiple Novel Genomic Structural Variants in Patient Leukemias. Blood. 136(Supplement 1). 33–34. 1 indexed citations
7.
Burian, Carol, et al.. (2019). Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation Utilizing Cladribine and Melphalan. Biology of Blood and Marrow Transplantation. 25(3). S196–S196.
8.
Mason, James R., et al.. (2015). Systolic pressure response to voluntary apnea predicts sympathetic tone in obstructive sleep apnea as a clinically useful index. Autonomic Neuroscience. 194. 38–45. 6 indexed citations
9.
Stuart, Robert K., Larry D. Cripe, Michael B. Maris, et al.. (2014). REVEAL‐1, a phase 2 dose regimen optimization study of vosaroxin in older poor‐risk patients with previously untreated acute myeloid leukaemia. British Journal of Haematology. 168(6). 796–805. 27 indexed citations
10.
Waalen, Jill, et al.. (2012). Effects of long-term cryopreservation on peripheral blood progenitor cells. Cytotherapy. 14(10). 1228–1234. 13 indexed citations
11.
Gollard, Russell, et al.. (2011). Intramedullary PNET of the Spine. Journal of Pediatric Hematology/Oncology. 33(2). 107–112. 11 indexed citations
12.
Schuster, Michael W., E. Anaissie, David D. Hurd, et al.. (2007). Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis. 5. 58–59. 2 indexed citations
13.
Bashey, Asad, Bridget Medina, Sue Corringham, et al.. (2007). Clinical Trial of Therapeutic Blockade of CTLA4 with Ipilimumab in Patients with Relapse of Malignancy Following Allogeneic Hematopoietic Transplantation.. Blood. 110(11). 1646–1646. 2 indexed citations
14.
Sala‐Torra, Olga, Michael R. Loken, Mary E.D. Flowers, et al.. (2006). Evidence of Donor-Derived Hematologic Malignancies after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation. 12(5). 511–517. 73 indexed citations
15.
16.
Bashey, Asad, Bridget Medina, Jiehua Zhou, et al.. (2005). Phase I study of a neutralizing monoclonal anti-CTLA4 antibody (MDX-010) in patients with relapse of malignancy after allogeneic hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 11(2). 5–5. 2 indexed citations
17.
Emmanouilides, Christos, et al.. (2001). A Randomized Phase II Study of Amifostine Used As Stem Cell Protectant in Non-Hodgkin Lymphoma Patients Receiving Cisplatin-Based Salvage Chemotherapy Prior to Stem Cell Transplant. Journal of Hematotherapy & Stem Cell Research. 10(6). 887–893. 5 indexed citations
18.
MacKenzie, Mairead, Madhusudan V. Peshwa, Theodore Wun, et al.. (2000). Immunotherapy of advanced refractory multiple myeloma with idiotype-pulsed dendritic cells (mylovenge). 96. 7 indexed citations
19.
Shea, Thomas C. & James R. Mason. (1992). Biology and Clinical Application of Peripheral Blood Stem Cells. Current topics in microbiology and immunology. 177. 205–214. 4 indexed citations
20.
Mason, James R., et al.. (1964). Fatal Chloroquine Poisoning: Two More Cases. JAMA. 188(2). 187–187. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ginette Schiby Breakdown of academic impact, for papers by J Bernard Breakdown of academic impact, for papers by Stephanie Schneider Breakdown of academic impact, for papers by Jacqueline Vuong Breakdown of academic impact, for papers by Kaoru Takase Breakdown of academic impact, for papers by Maya N. Polackal Breakdown of academic impact, for papers by Souichi Suenobu Breakdown of academic impact, for papers by J Pazdur Breakdown of academic impact, for papers by Satkiran S. Grewal Breakdown of academic impact, for papers by Harumi Y. Mukai
Rankless by CCL
2026